๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase i study of emetine hydrochloride (nsc 33669) in solid tumors

โœ Scribed by Michael J. Mastrangelo; Theodor B. Grage; Robert E. Bellet; Arthur J. Weiss

Publisher
John Wiley and Sons
Year
1973
Tongue
English
Weight
445 KB
Volume
31
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase I study of gemcitabine and docet
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
โœ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB ๐Ÿ‘ 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and

Phase I study of CI-958 in children and
Phase I study of CI-958 in children and adolescents with recurrent solid tumors
โœ Carola A. S. Arndt; Mark D. Krailo; Wen Liu-Mares; Peter M. Anderson; Gregory H. ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 63 KB ๐Ÿ‘ 2 views

BACKGROUND. CI-958 is a synthetic intercalating agent of a new chemical class, the benzopyranoindazoles, with promising preclinical activity. Its mechanism of action is thought to be stabilization of the cleavable complex of DNA with topoisomerase II, as well as DNA helicase blockade. It is thought

A Phase I study of raltitrexed and pacli
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors
โœ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 66 KB ๐Ÿ‘ 2 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a